Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
HPHA Stock Overview
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally.
Heidelberg Pharma Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €5.00 |
52 Week High | €8.68 |
52 Week Low | €3.41 |
Beta | -0.73 |
1 Month Change | -5.66% |
3 Month Change | 24.84% |
1 Year Change | -21.51% |
3 Year Change | 84.50% |
5 Year Change | 68.78% |
Change since IPO | -90.54% |
Recent News & Updates
Shareholder Returns
HPHA | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0.8% | 4.3% | -0.09% |
1Y | -21.5% | -31.4% | -12.9% |
Return vs Industry: HPHA exceeded the German Biotechs industry which returned -31.4% over the past year.
Return vs Market: HPHA underperformed the German Market which returned -12.9% over the past year.
Price Volatility
HPHA volatility | |
---|---|
HPHA Average Weekly Movement | 17.6% |
Biotechs Industry Average Movement | 8.1% |
Market Average Movement | 6.4% |
10% most volatile stocks in DE Market | 10.6% |
10% least volatile stocks in DE Market | 3.5% |
Stable Share Price: HPHA is more volatile than 90% of German stocks over the past 3 months, typically moving +/- 18% a week.
Volatility Over Time: HPHA's weekly volatility has increased from 10% to 18% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 89 | Jan Schmidt-Brand | https://heidelberg-pharma.com |
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. It is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for tumors; and HDP-XX for the treatment of solid/hematological tumors.
Heidelberg Pharma Fundamentals Summary
HPHA fundamental statistics | |
---|---|
Market Cap | €170.88m |
Earnings (TTM) | -€27.06m |
Revenue (TTM) | €2.40m |
71.2x
P/S Ratio-6.3x
P/E RatioIs HPHA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
HPHA income statement (TTM) | |
---|---|
Revenue | €2.40m |
Cost of Revenue | €4.27m |
Gross Profit | -€1.87m |
Other Expenses | €25.20m |
Earnings | -€27.06m |
Last Reported Earnings
Feb 28, 2022
Next Earnings Date
Jul 12, 2022
Earnings per share (EPS) | -0.79 |
Gross Margin | -77.69% |
Net Profit Margin | -1,127.16% |
Debt/Equity Ratio | -4,143.8% |
How did HPHA perform over the long term?
See historical performance and comparisonValuation
Is Heidelberg Pharma undervalued compared to its fair value and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
In this section, we usually try to help investors determine whether Heidelberg Pharma is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Heidelberg Pharma has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
Future Growth
How is Heidelberg Pharma forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score
1/6Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
-0.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HPHA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: HPHA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: HPHA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: HPHA's revenue (18.3% per year) is forecast to grow faster than the German market (4.8% per year).
High Growth Revenue: HPHA's revenue (18.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if HPHA's Return on Equity is forecast to be high in 3 years time
Past Performance
How has Heidelberg Pharma performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-23.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HPHA is currently unprofitable.
Growing Profit Margin: HPHA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: HPHA is unprofitable, and losses have increased over the past 5 years at a rate of 23.9% per year.
Accelerating Growth: Unable to compare HPHA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HPHA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).
Return on Equity
High ROE: HPHA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Financial Health
How is Heidelberg Pharma's financial position?
Financial Health Score
0/6Financial Health Score 0/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: HPHA has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: HPHA has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: HPHA has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: HPHA's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HPHA has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: HPHA has less than a year of cash runway if free cash flow continues to reduce at historical rates of 26.5% each year
Dividend
What is Heidelberg Pharma current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate HPHA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HPHA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HPHA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HPHA's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as HPHA has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
3.5yrs
Average management tenure
CEO
Jan Schmidt-Brand (63 yo)
9.67yrs
Tenure
€474,360
Compensation
Dr. Jur. Jan Schmidt-Brand has been the Chief Financial Officer of Wilex AG since September 01, 2012 and serves as its Member of The Executive Management Board and Chief Executive Officer. Dr. Jur. Schmidt...
CEO Compensation Analysis
Compensation vs Market: Jan's total compensation ($USD506.90K) is about average for companies of similar size in the German market ($USD670.79K).
Compensation vs Earnings: Jan's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: HPHA's management team is considered experienced (3.5 years average tenure).
Board Members
Experienced Board: HPHA's board of directors are seasoned and experienced ( 12 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10%.
Top Shareholders
Company Information
Heidelberg Pharma AG's employee growth, exchange listings and data sources
Key Information
- Name: Heidelberg Pharma AG
- Ticker: HPHA
- Exchange: XTRA
- Founded: 1997
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €170.879m
- Shares outstanding: 34.18m
- Website: https://heidelberg-pharma.com
Number of Employees
Location
- Heidelberg Pharma AG
- Gregor-Mendel-Strasse 22
- Ladenburg
- Baden-Württemberg
- 68526
- Germany
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/05/23 00:00 |
End of Day Share Price | 2022/05/23 00:00 |
Earnings | 2022/02/28 |
Annual Earnings | 2021/11/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.